Redeye comments on W5’s announcement of a major framework agreement for generators worth up to SEK50...
Redeye endorses SenzaGen’s continued collaboration with RIFM.
IRLAB Therapeutics has successfully completed the second and final of two pre-determined safety and ...
Redeye is encouraged by Nekkar’s acquisition of Globetech which was announced this morning.
Refine Group AB ("Refine", "Koncernen" eller "Bolaget") meddelade den 28 juni år 2024 att dotterbola...
Redeye konstaterar att Donanemab, under det kommersiella namnet Kisunla, som väntat fått ett fullt g...
Redeye initiates coverage on CoinShares (CS), a leading crypto asset manager holding a European mark...
Q2 preview: EBITA growth of 16% y-o-y In Q2, we expect easy growth comps to result in a sequential a...
Luxbright har levererat en första leverans av ett kundspecifikt röntgenrör till Fisica Inc.
Windon Energy Group (”Windon” eller ”bolaget”) meddelade den 2 juli år 2024 att bolaget har erhållit...
Cereno Scientific has released updates on its two most advanced clinical programmes.
Redeye comments on EG7’s acquisition of S6 which is the developer and publisher of the online multip...
Redeye offers a preview of Advenica's Q2 results set to be released on July 19th.
Redeye is only making minor changes to our estimates and valuation following the full-year report.
Ahead of Cibus' Q2 2024 report, we incorporate the acquisition of six properties, announced in late ...
Nettoomsättningen uppgick till 43,7 MSEK (44,4) i det fjärde kvartalet (februari-april) i Purefuns b...
Q2 likely similar to Q1 Q2 seems to have developed in a similar way to Q1, with the trend of longer ...
Our earnings bridge We expect Q2 clean EBIT of ~SEK 63m, up from SEK 5m in Q1'24 and SEK 57m in Q2’2...
Redeye shares its preview of BONESUPPORT’s Q2 2024e results, due 11 July.
Kinda Brave Entertainment Group AB (”Kinda Brave” eller ”Koncernen”) meddelade den 28 juni år 2024 a...
